Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 12;13:1020580. doi: 10.3389/fimmu.2022.1020580

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Muri, Schubart, Thorburn, Zamurovic, Holbro, Kammüller, Pluschke and Ispasanie

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Impact of complement inhibitors targeting the terminal pathway (C5), C3 and the AP (fB, fD) on the survival of Hib isolates (A–D) in sera taken prior to vaccination (Pre) or 2 weeks after vaccination with ActHIB (Post). Sera were diluted 1:5 and assayed with the preserved internal complement. Data shown in the graphs are with the highest inhibitor concentration tested (25 µM for the fB inhibitor iptacopan and the fD inhibitor CMS487, 100 µg/mL for the C3 inhibitor CP-40 and the anti-C5 mAb tesidolumab). The horizontal dotted line represents 50% survival of bacteria after 60 minutes incubation, as compared to control wells at time 0. Data for each inhibitor are triplicate technical replicates. SD, standard deviation.